

# Anal Cancer - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A0BDFD902DEEN.html>

Date: August 2020

Pages: 589

Price: US\$ 2,000.00 (Single User License)

ID: A0BDFD902DEEN

## Abstracts

Anal Cancer - Pipeline Review, H2 2020

### Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

### Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 19, 18, 2 and 5

respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

## **Reasons to Buy**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Anal Cancer - Overview

Anal Cancer - Therapeutics Development

Anal Cancer - Therapeutics Assessment

Anal Cancer - Companies Involved in Therapeutics Development

Anal Cancer - Drug Profiles

Anal Cancer - Dormant Projects

Anal Cancer - Discontinued Products

Anal Cancer - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Anal Cancer, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020 (Contd..1), H2 2020  
Products under Development by Companies, H2 2020 (Contd..2), H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Anal Cancer - Pipeline by Antiva Biosciences Inc, H2 2020  
Anal Cancer - Pipeline by AstraZeneca Plc, H2 2020  
Anal Cancer - Pipeline by Bayer AG, H2 2020  
Anal Cancer - Dormant Projects, H2 2020  
Anal Cancer - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Anal Cancer, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Top 10 Routes of Administration, H2 2020  
Number of Products by Stage and Top 10 Routes of Administration, H2 2020  
Number of Products by Top 10 Molecule Types, H2 2020  
Number of Products by Stage and Top 10 Molecule Types, H2 2020

### COMPANIES MENTIONED

Antiva Biosciences Inc  
AstraZeneca Plc  
Bayer AG  
Beijing Kangle Guardian Biotechnology Co Ltd  
Biocon Ltd  
Biomimetix JV LLC  
BNOAT Oncology Inc  
Boehringer Ingelheim International GmbH  
Bristol-Myers Squibb Co  
Cleveland BioLabs Inc  
Cue Biopharma Inc  
CytomX Therapeutics Inc  
Eisai Co Ltd  
Eli Lilly and Co  
F. Hoffmann-La Roche Ltd  
Fujifilm Holdings Corp  
Gilead Sciences Inc  
Hookipa Pharma Inc  
IMV Inc  
Incyte Corp  
Invectys SA  
ISA Pharmaceuticals BV

Merck & Co Inc  
Merck KGaA  
Mereo Biopharma Group Plc  
Molecular Partners AG  
Onconova Therapeutics Inc  
Ono Pharmaceutical Co Ltd  
PDS Biotechnology Corp  
Privo Technologies Inc  
Shanghai Zerun Biotechnology Co Ltd  
Sotio AS  
SQZ Biotechnologies Co  
THEVAX Genetics Vaccine USA Inc  
Transgene SA  
Treadwell Therapeutics Inc  
Turnstone Biologics Inc  
Virion Therapeutics LLC  
Xencor Inc

## I would like to order

Product name: Anal Cancer - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A0BDFD902DEEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A0BDFD902DEEN.html>